Trial reportPain medicine (Malden, Mass.)2026
The effects of EXOPULSE Mollii Suit in patients with fibromyalgia: a double-blind randomized sham-controlled trial (EXOFIB2).
Trial report in Pain medicine (Malden, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
importanceNeuromodulation via transcutaneous electrical stimulation shows promise in fibromyalgia, but conventional devices have limited coverage. The EXOPULSE Mollii Suit is a full-body garment with 58 electrodes, potentially addressing widespread pain.
objectiveThis study evaluated repeated Mollii Suit sessions on disease impact, pain, and fibromyalgia-related symptoms.
designThis study consisted of a randomized, sham-controlled crossover phase and an open-label phase.
settingInclusion occurred in a hospital setting.
participantsAdults with fibromyalgia were enrolled.
interventionsIn this double-blind, randomized, sham-controlled crossover trial (phase 1), participants received 2 weeks of daily active or sham stimulation (1 h/day), followed by a ≥2-week washout and crossover. A 4-week open-label extension (phase 2) was proposed. MAIN OUTCOMES AND MEASURES: The primary outcome was the Fibromyalgia Impact Questionnaire (FIQtotal). Secondary outcomes included pain, anxiety, depression, and quality of life.
resultsTwenty-two patients completed phase 1 and 20 completed phase 2. In phase 1, FIQtotal scores significantly decreased following the active intervention (66.06 ± 13.46 to 50.81 ± 23.22, Friedman's P < .01, Bonferroni-adjusted Dunn's P < .05), whereas no significant effects were observed following the sham intervention. Improvements were also observed in several secondary measures (pain catastrophizing and some quality of life domains). Phase 2 also revealed significant benefits in FIQtotal as well as several secondary outcomes. No severe adverse events occurred at any time.
conclusionsEXOPULSE Mollii Suit led to clinically meaningful improvements in fibromyalgia impact and related outcomes. RELEVANCE: The results of this work are in line with those of previous trials and support its potential as a home-based neuromodulation therapy for fibromyalgia. Future large-scale studies would help further understand the effects of this medical device.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.